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Abstract
Background: Mutations linked to early onset, familial forms of Alzheimer’s disease (FAD) are found most frequently in
PSEN1, the gene encoding presenilin-1 (PS1). Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and
presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the c-secretase complex and contributes to
the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (Ab) peptides. Although there is a growing
consensus that FAD-linked PS1 mutations affect Ab production by enhancing the Ab1–42/Ab1–40 ratio, it remains unclear
whether and how they affect the generation of APP intracellular domain (AICD). Moreover, controversy exists as to how PS1
mutations exert their effects in different experimental systems, by either increasing Ab1–42 production, decreasing Ab1–40
production, or both. Because it could be explained by the heterogeneity in the composition of c-secretase, we purified to
homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, DE9, or P436Q.
Methodology/Principal Findings: We took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to
generate different stable cell lines overexpressing human c-secretase complexes with different FAD-linked PS1 mutations. A
multi-step affinity purification procedure was used to isolate semi-purified or highly purified c-secretase complexes. The
functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of c-secretase
activity phenotype, in terms of Ab1–40, Ab1–42 and APP intracellular domain productions in vitro.
Conclusion/Significance: Our data support the view that PS1 mutations lead to a strong c-secretase loss-of-function
phenotype and an increased Ab1–42/Ab1–40 ratio, two mechanisms that are potentially involved in the pathogenesis of
Alzheimer’s disease.
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Introduction
Since their discovery in 1995 and their association with early
onset familial Alzheimer’s disease (FAD) [1,2], the presenilin genes
PSEN1 and PSEN2 have been widely studied, and the complexity
of their biological role is becoming increasingly evident. PSEN1
and PSEN2 encode transmembrane proteins PS1 and PS2,
respectively, that constitute the catalytic core of c-secretase, the
founding member of an emerging class of unconventional,
Intramembrane-Cleaving Proteases (I-CLiPs) [3]. Active c-secre-
tase is a multiprotein complex composed of PS1 or PS2 together
with nicastrin (NCT), the anterior pharynx-defective protein 1
(APH1), and the presenilin enhancer 2 (PEN2). Experimental
evidence such as the binding of transition-state analogue c-
secretase inhibitors to PS1 [4], as well as the abolishment of c-
secretase activity when PS1 lacks the aspartate residues critical for
proteolysis [4,5,6], have confirmed that presenilins harbour the
active site of the enzymatic complex.
PS1 and PS2 play fundamental roles in cell signalling as part of
the c-secretase complex. The latter cleaves numerous type-I
membrane proteins in their transmembrane domain [7], releasing
their corresponding intracellular domains, which are capable of
influencing gene expression. For some substrates like NOTCH1 or
ERBB4, the c-secretase cleavage is essential for their biological
function, whereas for other substrates like DCC or NEUREXIN-
3b [8], the possible role of the cleavage in signalling events has not
been formally established (see [9] for a review). The amyloid
precursor protein (APP) is processed by the successive actions of b-
secretase (BACE1) and c-secretase, generating amyloid-beta
peptides (Ab) of different lengths, ranging from 37 to 46 amino
acids [10]. Cleavage of the APP C-terminal fragments (APP-CTFs)
by c-secretase also releases the APP intracellular domain (AICD),
which has been recently involved in the regulation of brain ApoE
expression, a major genetic determinant of AD, and in cholesterol
metabolism [11]. In addition, PS1 has been shown to interact with
a growing list of proteins that modulate c-secretase activity
[9,12,13,14].
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In a pathological context, 185 missense mutations in PSEN1 and
13 mutations in PSEN2 have been identified and found to be
associated with FAD (www.molgen.ua.ac.be/ADMutations). It
was initially suggested that such mutations lead to a toxic gain of
function because they are associated with a relative increased
production of longer and more hydrophobic Ab species, mainly
Ab1–42, that accumulate and aggregate early in the course of the
disease [15,16]. Similar phenotypes have been observed by
independent groups in cell-based studies performed with different
mammalian cell lines [17,18,19,20,21,22]. Despite this growing
consensus, the above-mentioned studies provided conflicting
results regarding the relative proportions of Ab42, Ab40, and
AICD resulting from the PSEN mutations. On one hand, a gain-
of-function phenotype was suggested due to the observed increase
in Ab42 production, accompanied or not with reduced Ab40
production, thereby leading to an increased Ab42/Ab40 ratio. On
the other hand, reduced AICD production suggested a loss-of-
function phenotype [20]. Differences in the methodologies and cell
types used to assess the effects of PSEN mutations on Ab and
AICD productions can explain this controversy as to how PS
mutations exert their effects. For example, endogenous PS has
been suggested to affect such analysis, as the FAD-linked PSEN1
mutations led to a decrease in the total amount of Ab generated in
PS1 and PS2 double knockout cells [23]. Next, it has been
reported that c-secretase complexes are heterogeneous in
composition (with two PS genes and three APH1 isoforms, six
combinations of c-secretase are possible), with distinct functional
properties influencing the relative amount of Ab species generated
[24]. In order to investigate the biochemical and functional
properties of c-secretase in cell-free systems, we and others have
recently purified this enzymatic complex to homogeneity
[25,26,27]. In particular, protocols for the high-grade purification
of proteolytically active c-secretase constituted of NCT, APH1aL,
PEN2 and wild-type PS1 [26,27] allowed the reconstitution of 3D
structures at 15 A˚ and 12 A˚ resolution by EM and cryo-EM and
gave new insights on the structure and activity of the enzyme
[28,29]. However, these studies were exclusively focused on the
wild-type PS1. Here, we report for the first time the functional
characterization of highly purified and homogenous human c-
secretase particles carrying different FAD-linked PS1 mutants.
Our biochemical and functional findings strongly suggest that
pathogenic mutations in PSEN1 cause a loss of c-secretase activity.
Results
Generation, selection and characterization of stable cell
lines overexpressing c-secretase complexes with FAD-
linked PS1 mutants
In order to facilitate high-grade purification of homogenous
human c-secretase complexes containing different PS1 variants,
we took advantage of a previously generated mouse embryonic
fibroblast (MEF) cell line that lacks the two presenilins (PS1/22/2)
[30,31]. Our global strategy consisted in producing stable cell
lines, on a PS1/22/2 background, that overexpress tagged
versions of the three human c-secretase subunits NCT, APH1
and PEN2 together with different variants of human PS1, and to
purify the different human c-secretase complexes by three
sequential affinity purification steps. This strategy allowed us to
exclude a possible co-purification of mouse c-secretase compo-
nents. First, a parental cell line was generated by co-transducing
lentiviral vectors of human NCT-V5 (hNCT-V5), human
APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-
hPEN2) into MEF PS1/22/2. Lentivectors are stably integrated
into the cell genome and allow the generation of cell lines
overexpressing multiple genes in a short period of time. Next, the
clone expressing the highest levels of all three recombinant
proteins was selected (designated c - PS1/2) and used as the
parental cell line that was further transduced with lentivectors
carrying the following different human PS1 variants: PS1-WT,
three dominant-negative forms of PS1 that lack the crucial,
catalytic site aspartate residues (D257A, D385A, and both
D257A/D385A referred to as DDAA later in the article), and
three FAD-linked PS1 mutants (L166P, DE9 and P436Q, with
mean disease onset at 24 years, 45.5 years and 28.3 years,
respectively).
For each PS1 variant, two individual clones were selected based
on the expression levels of the recombinant proteins, and
extensively characterized (Figure 1). To distinguish those cell lines
overexpressing all c-sectease components from wild-type MEFs,
they are collectively designated c-MEFs. As shown in Figure 1A,
the analysis of total protein extracts confirmed that PS is required
for the maturation of NCT and the stability of PEN2 [23,32]. As
expected, and when compared to the parental c- PS1/2 cell line,
higher levels of the mature form of NCT were observed in all PS1-
overexpressing clones. In contrast to PEN2, APH1aL levels were
relatively similar in all PS1 clones and the parental cell line.
Indeed, and as previously reported [23,32], PEN2 levels were
higher in the clones overexpressing WT PS1 and FAD-linked PS1
mutants, and to a lesser extent in the clones overexpressing the
dominant negative forms of PS1. Interestingly, PEN2 migrated on
the gel as an apparent double band, possibly reflecting a post-
translational modification. Different patterns of PS1 expression
and autoproteolysis were observed in the different clones. First,
and in sharp contrast to the other clones, those expressing PS1-
WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-
CTF fragments compared with full-length PS1 (PS1-FL;
Figure 1A). As estimated by densitometry, the NTF fragments of
PS1-WT and PS1-L166P account for 8762% and 7967% of total
PS1 (PS1-NTF+PS1-FL), respectively. Next, the PS1-DE9 clones
did not show any detectable NTF or CTF fragments, as previously
described [33], while P436Q and the three dominant negative
variants of PS1 were characterized by low levels of PS1-NTF and
PS1-CTF fragments, suggesting that these variants were less prone
to endoproteolysis.
We next investigated the effects of PSEN1 mutations on the
processing of endogenous APP. As expected, and as indicated by
increased levels of intracellular APP-CTFs (a common character-
istic among known substrates in response to c-secretase pharma-
cological inhibition), the activity of c-secretase was significantly
altered in the PS deficient parental c - PS1/2 cell line as well as in
all clones expressing dominant negative forms of PS1 (Figure 1B).
In the clones expressing PS1-WT, APP-CTFs were almost
undetectable due to high c-secretase activity, while clones
expressing PS1-L166P or PS1-P436Q displayed APP-CTF
accumulation. In PS1-DE9 clones, a mild APP-CTF accumulation
was observed (Figure 1B). Although a poor recovery of c-secretase
activity for the PS1-L166P and a comparatively better perfor-
mance of PS1-DE9 have been reported by others under similar
experimental conditions [23], the potential of PS1-P436Q
mutation to restore the processing of endogenous APP-CTFs has
never been assessed [34,35]. Importantly, all observations
described above for the cells overexpressing simultaneously
hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1
variants are very consistent with those made in MEF PS1/22/2
cells overexpressing only the PS1 variants, in the absence of the
other c-secretase components (cf. Figure S1A). These data suggest
that the effect of FAD mutations in PS1 on APP-CTFs
Purified c-Secretase Complexes with PS1 Mutations
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accumulation was similar in presence or absence of other human
components of the c-secretase.
Next, we further investigated the effect of PS1 variants on the
cellular production/secretion of Ab species. For this purpose, and
as described elsewhere [36], we used an APP-based c-secretase
substrate with a Flag tag at its C-terminus (SPA4CT-Flag). This
substrate was transduced in the above-described c-secretase
overexpressing stable cell lines (c-MEFs) as well as in wild-type
MEFs, and APP-CTFs and Ab levels were measured in cell lysate
and cell media, respectively (Figure 2). Under these conditions, the
overexpression of SPA4CT-Flag led to an accumulation of two
bands corresponding to the exogenous substrate, associated with a
concomitant decrease of endogenous APP-CTFs levels (Figure 2A
and Figure S2). As estimated by ELISA, a three-fold increase in
Ab1–40 and Ab1–42 levels was observed in the cell culture media
of cell lines overexpressing human c-secretase (c-MEF WT), in
comparison to untransduced WT MEFs (Figure 2B). Also, the
average Ab1–42/Ab1–40 ratios were not significantly different in
those cell lines (Mean 6 SD: c-MEF WT#5: 0.3060.01; c-MEF
WT#8: 0.2960.01; WT MEF: 0.1960.06). Next, overexpression
of SPA4CT-Flag in c-MEFs led to the pronounced intracellular
accumulation of APP-CTFs in cells overexpressing the PS1
aspartate mutants (Figure 2C), and to the secretion in the cell
culture media of different Ab levels as measured by ELISA
(Figure 2D). First, only traces of both Ab1–40 and Ab1–42 were
detected in c-MEFs overexpressing PS1 with aspartate mutants.
Next, c-MEFs overexpressing PS1 with FAD-linked mutations
displayed a pronounced variability in Ab levels when compared to
Figure 1. Generation of stable cell lines overexpressing all human c-secretase components with FAD-linked PS1 variants. MEF PS1/
22/2 were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by
limiting dilution to generate a cell line, designated as c- PS1/2, that overexpresses high amount of the three subunits. c- PS1/2 MEFs were further
transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned. Each clone,
derived form the c- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol c and followed by the number
of the clone (c-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/22/2. Two clones per c-secretase variant were selected
for characterization. (A–B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4–
12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the c-secretase core components NCT (NCT164), PS1 (NTF, MAB1563;
CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B). b-Actin was used as a loading control. Each lane
represents one selected clone. CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal
fragment, O: O-glycosylated.
doi:10.1371/journal.pone.0035133.g001
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the wild-type clones. Overall, the average Ab1–40 levels were
decreased in these cell lines (Mean of two clones in pg/mL 6 SD:
WT: 224.660.1, L166P: 84.3634.2, DE9: 167.2640.7, P436Q:
82.8674.7), while the Ab1–42 levels were increased (Mean of two
clones in pg/mL 6 SD: WT: 69.967.9, L166P: 310.7681.0,
DE9: 94.4618.5, P436Q: 141.1698.5). Consistent with previously
reported data, the Ab1–42/Ab1–40 ratios were increased in all c-
MEF clones overexpressing PS1 with FAD-linked mutations
(Figure 2D) (Mean of two clones pg/mL 6 SD: WT:
0.3160.03, L166P: 3.860.58, DE9: 0.660.03, P436Q: 2.060.59).
FAD-linked PS1 mutations alter the activity of semi-
purified c-secretase complexes
We next assessed the activity of c-secretase with FAD-linked
PS1 mutations in microsomal extracts of c-MEFs. Membrane
protein extracts were prepared and c-secretase activity was
assayed on an exogenous recombinant APP-based substrate
consisting of the C-terminal 99 amino acid residues of APP, and
referred to as C100-Flag (Figure 3A). The generation of the
cleavage product AICD-Flag was detected by Western blot
analysis and measured by densitometry. As shown in Figure 3A,
the levels of AICD-Flag generated from the PS1-L166P and
PS1-DE9 clones accounted for 4261% and 1366% of that in
the PS1-WT clones, respectively. AICD-Flag was undetectable
in the clones expressing PS1-P436Q as well as in the three
dominant negative aspartate PS1 variants. Similar results were
observed in MEF PS1/22/2 cells overexpressing only the PS1
variants, in the absence of the other human c-secretase
components (Figure S1B).
We next performed activity assays under semi-purified
conditions. To do so, c-secretase complexes from the different
clones were co-immunoprecipitated from microsomal extracts
and their activities were assayed in vitro with the C100-His
substrate. Two immunoprecipitation protocols using two affinity
resins (anti-Flag M2 and anti-HA 3F10, targeting respectively
Flag-PEN2 and APH1aL-HA) were compared to exclude a
possible heterogeneity of c-secretase complexes potentially
generated under such conditions. As shown in Figure 3B, the
anti-Flag and anti-HA resins immunoprecipitated similar levels of
NCT, PS1 and PEN2 and the activity of the c-secretase
complexes was similar regardless of the affinity resins used
(Figures 3B). In agreement with the assays performed using
microsomal extracts (Figure 3A), those performed with semi-
purified complexes revealed that FAD-linked mutants drastically
reduced AICD generation, when compared to PS1-WT
(Figure 3B). Furthermore, levels of Ab1–40 produced from
PS1-L166P, PS1-DE9 and P436Q variants fell respectively to
,6%, ,1.5% and ,0.5%, when compared to these produced
from PS1-WT c-secretase. Following the same tendency, Ab1–42
levels generated from PS1-L166P, PS1-DE9 and PS1-P436Q c-
secretase variants were respectively estimated to ,20%, ,5%
and ,3% of these produced with PS1-WT-containing complexes.
The Ab1-42/Ab1–40 ratio measured for WT c-MEFs was
consistent with our cell-based data (compare Figures 2D and 3C),
validating our in vitro experimental conditions. Interestingly, an
overall Ab1–42/Ab1–40 ratio of ,1 was estimated for all PS1
mutants, with the exception of P436Q#4 (,2). However, in the
latter, the ratio may have been overestimated because the Ab1–
40 levels measured were at the detection limit. This similarity in
the Ab1–42/Ab1–40 ratios generated by the different mutants
has, to the best of our knowledge, never been observed in
previous studies.
Highly purified c-secretase complexes with FAD-linked
PS1 mutants display a loss-of-function phenotype
In order to further investigate how PS1 variants affect APP-
CTF cleavage and to validate our observations performed in semi-
purified conditions, we purified to homogeneity c-secretase
complexes from the selected clones described in Figure 1. The
purification process (described in details under Materials &
Methods and depicted in Figure 4A) involved three sequential
affinity purifications starting from microsomal extracts. Since all
cell lines were generated on a PS knockout background, this
strategy allowed us to purify exclusively and selectively c-secretase
complexes made of human components. As highlighted in
Figure 4B, our protocol led to the production of stable, high
molecular weight c-secretase complexes (HMWCs) with an
apparent molecular mass on Blue Native (BN)-PAGE of
,350 kDa, which is consistent with previous reports [26,27,37].
The silver stained particles on the BN gel confirmed the high
purity of these complexes (Figure 4B, upper panel), for which the
identity was established by cross-reactivity with antibodies specific
to NCT and PS1 (Figure 4B, lower panels). As the main goal of
this experiment was to compare the efficacy of the different c-
secretase complexes to process APP-based substrates, it is
important to note that the final yields of the complexes purified
from the different clones were very similar (Figure 4B), thus
facilitating further comparative analyses. The immunoblot analysis
of the purified complexes (Figure 4C) confirmed the presence of all
core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1)
and globally recapitulates the maturation processes observed in the
Figure 1. Interestingly, the relative PS1-NTF/CTF to PS1-FL
ratios in the purified c-secretase complexes containing the three
PS1 dominant-negative or the PS1-P436Q variants were higher
than those estimated in the whole cell extracts before purification
(Figure 1A), indicating that endoproteolysis of PS1 was not
completely abolished by these mutations. To assess how FAD-
linked mutations in PS1 affect c-secretase activity in these purified
complexes, we performed in vitro assays by using C100-Flag
substrate (Figure 3A) and equal amounts of the different purified
complexes, immediately after the purification to avoid freezing/
thawing cycles that might affect enzymatic activity. As shown in
Figure 5A, c-secretase activity based on AICD-Flag production
was easily detected in complexes purified from the two PS1-WT
clones. This is in sharp contrast to the other purified complexes
that did not generate detectable AICD under our experimental
conditions (Figure 5A). Next, sandwich ELISAs directed against
Ab1–40 and Ab1–42 were performed in order to further
characterize the specific activity of the purified complexes.
Reflecting the levels of AICD and considering the detection limits
of our sandwich ELISA, the production of both Ab species by c-
secretase complexes containing PS1-WT was at least 10-fold
higher than in complexes with the FAD-linked or dominant-
negative PS1 variants (Figure 5B). The Ab1–42/Ab1–40 ratio
measured in PS1-WT c-secretase complexes (,0.22) was similar to
that previously reported [26,27], thus excluding a possible
qualitative alteration of c-secretase activity with this protocol.
Together, our results strongly support the hypothesis that the
pathogenic L166P, DE9, and P436Q mutations in PSEN1 cause a
drastic loss (at least 90% as estimated by ELISA) of c-secretase
activity.
Discussion
Several conflicting results as to how Alzheimer’s disease-linked
mutations in PSEN1 affect the processing of APP by c-secretase
have been reported. First, it has been previously reported that
Purified c-Secretase Complexes with PS1 Mutations
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transgenic animals with FAD-linked PS1 mutations show increas-
ing brain levels of Ab1–42 [15,38]. Since Ab1–42, the first Ab
specie deposited in the brain of AD patients [16,39], is more prone
to aggregation when compared to shorter Ab species [40,41,42], it
has been implicated in the seeding of amyloid plaques in AD
patients with PSEN1 mutations [43]. This was further validated in
vivo as the overexpression of PS1 mutants in APP transgenic mice
accelerated the rate of Ab accumulation and deposition in the
brain [44,45]. However, Bentahir and colleagues challenged this
view by showing that several PSEN1 mutations were also capable
Figure 2. Ab production in cell lines overexpressing human c-secretase components with FAD-linked PS1 variants. WT MEF, c-MEF
and c - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal
peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus. Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on
12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C). Ab1–40 and Ab1–42
levels were also measured in the corresponding cell culture media (B, D). Data corresponds to three independent experiments (Mean 6 SEM).
doi:10.1371/journal.pone.0035133.g002
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Figure 3. Enzymatic activity of partially purified c-secretase complexes with FAD-linked PS1 mutants. (A) c-Secretase activity assays
performed with c-MEF and c - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer. Equal protein levels from the different extracts were
diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37uC with lipids and 1 mM of recombinant human APP-based substrate (C100-Flag).
Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563). The relative amounts of AICD-Flag generated in
the reactions, reflecting c-secretase activity, were estimated by densitometry. PS1 immunostaining was used to assess the amount of input material.
(B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4uC with either anti-Flag M2 or anti-HA affinity resins, and
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to decrease total Ab production in PS1/PS2 knockout cells [23].
These findings suggested that endogenous PS1 and PS2 may
influence the mutant phenotype in cells or in vivo. By extension, we
hypothesized that the other components of c-secretase, namely
APH1, NCT and PEN2, may influence the mutant phenotype as
well. Indeed, c-secretase complexes are heterogeneous in compo-
sition due to the existence of two human APH1 genes, APH1a and
APH1b, and two splicing isoforms of APH1a (S and L), as well as
two presenilin genes, PSEN1 and PSEN2. Therefore, it is plausible
that a single mutation in PSEN1 confers different catalytic
properties to distinct c-secretase subtypes. This hypothesis is
supported by recent investigations showing that APH1 variants
can modulate Ab profiles. When compared to APH1aS or L,
overexpression of APH1b in MEF knockout for all APH1 genes
led to increased production of longer Ab species [24]. With this
regard, it is important to note that all four mouse variants of APH1
are expressed in the MEF cell line used in previous studies [23]
and employed here (cf. Figure S3). Since the phenotype of PS1
mutations have mainly been assessed in vivo or in cell-based
systems, we investigated the effects of FAD-linked PS1 mutants on
the processing of APP-CTFs in cell-free systems, by using semi-
purified and purified enzymatic complexes isolated from MEF
PS1/PS2 double knockout cells stably overexpressing differentially
tagged human c-secretase components. Under these conditions,
the biochemical and functional properties of c-secretase complexes
bearing either FAD-linked PS1 mutants (L166P, DE9, and
P436Q), dominant-negative forms of PS1 or wild-type PS1 were
characterized. The activity of c-secretase with PS1-WT was
similar to that reported for c-secretase purified from our CHO
cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT
[26,27], that resulted in Ab1–42/Ab1–40 ratios between 0.1 and
0.3. In contrast, we found a major loss in the activity of c-secretase
complexes containing either the dominant-negative PS1 variants
or the FAD-linked PS1 mutants. Although a total loss of activity
was expected for the dominant negative forms of c-secretase
[5,6,32], the drastic loss of activity seen here with the FAD-linked
PS1 mutants was unexpected. Indeed, the PS1-L166P variant has
previously been reported to increase Ab1–42 levels both in vivo
[46] and in vitro [20], in the presence of endogenous PS1, PS2 and
APH1 components. In contrast, Bentahir and colleagues found
that PS1-L166P decreased both Ab1–40 and Ab1–42 production
in a PS knockout background. These results are consistent with
our in vitro data, although the reduction in Ab1–42 and Ab1–40
production was more pronounced in our system. However, they
differ from our cell-based data in which we observed an increase in
Ab1–42 associated with a decrease in Ab1–40. Taken together,
these data suggest that the overexpression of the other human
components of c-secretase can influence the phenotype of FAD-
linked mutations. Another possible explanation for these discrep-
ancies comes from the use, in previously described cellular systems,
of APP carrying the Swedish mutation (K670M/N671L)
[20,23,46]. Initially, this APP variant was shown to enhance the
production of all Ab species by favouring its b-secretase cleavage
[47,48]. However, Munter and colleagues recently demonstrated
that the APP Swedish mutation can also affect the specificity of the
c-secretase cleavage [49]. In particular, these authors showed that
over-expression of APP Swedish in a neuronal cell line led to a 4-
fold increase in secreted Ab42, associated with only a 2-fold
increase of total Ab, compared with the wild-type APP. Therefore,
one cannot exclude the possibility of differential interactions
between PS1-WT or PS1 variants and different APP variants, as
suggested earlier [50].
As far as the PS1-DE9 mutant is concerned, previous cell-based
studies have reported a decrease in Ab40 levels associated with an
increase in Ab42 levels [51,52], or no changes in Ab40 levels
despite increased Ab42 levels [53], or a decrease in both Ab
species [23]. In the present study, Ab1–40, Ab1–42, as well as
AICD levels generated from purified c-secretase complexes with
PS1-DE9 were close to the limit of detection, resulting in a loss of
at least 95% of the c-secretase activity compared to wild-type PS1.
Similarly, we found a near to complete loss of c-secretase activity
for complexes with the aggressive PS1-P436Q mutant (mean
onset: 28.3 years) [54]. Consistent with a recent study [35], and in
contrast to PS1-L166P, the maturation of the full-length PS1-
P436Q protein into PS1-NTF and PS1-CTF was impaired.
Interestingly, the same study also reported that P436Q variant
showed a decreased c-secretase activity and Ab40 and Ab42
secretion in PS1/PS2 double knockout cells (,75% or ,50% of
the control for Ab40 or Ab42, respectively), but to a lesser extent
than what we measured in this study (more than 97% for both Ab
species).
Overall, our data show that, under our experimental conditions,
the FAD-linked PS1 mutants cause a drastic loss of activity (at least
90%) in the highly purified and homogeneous as well as semi-
purified c-secretase complexes. This loss-of-function is asymmet-
rical as Ab1–42 levels were relatively less affected than Ab1–40
levels. Interestingly, the ratio between the two Ab species was
similar for the variants tested here (,1), suggesting a common
modulatory mechanism. Our findings further support a model in
which the subtype of c-secretase containing APH1aL and FAD-
linked PS1 mutants generates a higher Ab42/Ab40 ratio
compared to PS1-WT, as previously observed in vivo [15,38].
Taken together, the overall reduction in Ab levels strongly suggest
that other regulatory mechanisms or cellular components may
exist and account for the strong amyloid pathology observed in
AD patients carrying these FAD-linked PSEN1 mutations. In
agreement with this hypothesis, we report that the phenotype of
FAD-linked PSEN1 mutations is different whether we consider the
cell-based or the cell-free conditions. Indeed, even if Ab42/Ab40
ratios were globally increased in both experimental conditions, Ab
production was strikingly different.
One possible explanation would be that specific subtypes of c-
secretase complexes are less affected than others by PSEN1
mutations. For instance, it remains unknown whether c-secretase
complexes carrying APH1b or APH1aS are similarly affected by
PSEN1 mutations. In support to that regard, Winkler and
colleagues recently purified human c-secretase with PS1-L166P
and observed that such complexes, containing both APH1a and
AHP1b, led to increased Ab1–42 production associated with
decreased Ab1–40 production, as compared to the PS1-WT
complexes. Another possible explanation would be that purified c-
secretase complexes lack binding partners modulating the
submitted to a C100-His assay according to the same protocol as in (A). Protein samples were separated by SDS-PAGE and analysed by
immunostaining for c-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2)). AICD-His cleavage products were immunostained with
an anti-APP-CTF antibody (A8717). *Indicates a non-specific band corresponding to the IgG light chains. (C) Ab1–40 and Ab1–42 were quantified by
sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of Ab1–40 levels generated by the two wild-type
clones. Ab1–42/Ab1–40 ratios are indicated on the top of the bars. The results were confirmed in three independent experiments and a
representative dataset is shown.
doi:10.1371/journal.pone.0035133.g003
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Figure 4. High-grade purification of human c-secretase complexes with FAD-linked PS1 mutants. (A) Schematic representation of the c-
secretase purification process. Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human c-secretase
complexes containing different PS1 variants. Next, these cell lines were used for a multi-step purification procedure as described in the material and
methods. (B) Blue-Native PAGE analysis of purified c-secretase complexes made of different PS1 variants. Equal volumes of the different purified c-secretase
preparations were separated by native-PAGE on a 4–16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle
panel) or PS1-NTF (ab10281, bottom panel) as indicated. c-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of
,350 kDa. Note that the levels of HMWCswere similar for all clones. (C) Equal volumes of purified c-secretase complexes with FAD-linked PS1mutants were
separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-
HA (3F10), or anti-Flag (M2) antibodies. Two independent purifications were performed on each clonewith similar results. A representative dataset is shown.
doi:10.1371/journal.pone.0035133.g004
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processing of APP-based substrates, due to purification conditions
affecting physical interactions of proteins. These include TMP21
or the recently reported c-secretase activating protein (GSAP)
[12,13]. Further biochemical analyses are needed to test this
hypothesis.
The loss of activity in c-secretase containing PS1 variants also
leads to decreased generation of AICD. As AICD is involved in the
transcriptional regulation of several genes, including the neprilysin
[55], and the lipoprotein receptor, LRP1 [11], it is likely that
mutations in PSEN1 impair the regulation of these genes in vivo.
For instance, it is possible that unknown genes transcriptionally
regulated in vivo by the AICD might influence Ab metabolism in
return. In support to these views, Veeraraghavalu and colleagues
recently demonstrated that Notch signalling was impaired in
transgenic mice overexpressing PS1 mutants, albeit in the presence
of endogenous PS1-WT and all APH1 isoforms [56]. They found
decreased self-renewal and differentiation of neuronal precursor
cells in the subventricular zone, suggesting that the loss-of-function
phenotype of PSEN1 mutations can also be observed in
heterogeneous conditions. These results are reminiscent of the
previous report from Saura and colleagues showing that
conditional inactivation of both presenilins in vivo induces age-
dependent neurodegeneration associated with memory impair-
ment [57]. Altogether, the above-described data suggest that
alternative pathways of neurodegeneration related to loss of c-
secretase functions are possible and relevant to AD. They further
support the concept that modulating rather than inhibiting c-
secretase activity would be a more appropriate therapeutic strategy
for AD [58]. Supporting this view, the c-secretase inhibitor
Semagacestat tested in phase III clinical trials not only failed to
slow cognitive decline in patients with mild-to-moderate AD, but
actually made it worse [59].
Collectively, our findings support a model in which FAD-linked
mutations in PSEN1 likely induce Ab pathology by perturbing the
relative ratio between Ab species and by impairing developmental
and cellular signalling pathways controlled by c-secretase
substrates. This deleterious dual effect might explain why FAD-
linked PSEN1 mutations cause early onset Alzheimer’s disease.
Figure 5. Enzymatic activity of highly purified c-secretase complexes with FAD-linked or aspartate PS1 mutants. Equal amounts of the
different purified c-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3. The resulting
cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and
by sandwich ELISA for Ab1–40 or Ab1–42 (B). Note that the levels of Ab produced from FAD-linked c-secretase complexes were all in the non-linear
range of the ELISA standards, close to the detection limit. Whenever possible, Ab1–42/Ab1–40 ratios were quantified and indicated on the top of the
bars. Two independent purifications were performed on each clone and similar results were obtained. A representative dataset is shown.
doi:10.1371/journal.pone.0035133.g005
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Since it has been established that Ab and AICD are generated
following the processing by c-secretase at two distinct gamma- and
epsilon-cleavage sites in APP [60], further investigation is now
required to better understand whether and how FAD mutations in
PS1 differentially affect the epsilon versus gamma-cleavage sites in
APP, as well as in other known c-secretase substrates.
Materials and Methods
DNA Constructs and mutagenesis
NCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human
cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard
Medical School and Brigham and Women’s Hospital, Boston,
MA, USA). PS1 DE9 cDNA was obtained from C. Saura
(Universitat Auto`noma de Barcelona, Spain). PS1 D257A and
PS1 D385A cDNAs were obtained from M. Wolfe (Harvard
Medical School and Brigham and Women’s Hospital, Boston,
MA, USA). Mutations in PSEN1, namely, L166P and P436Q,
were generated by PCR-based mutagenesis on the plasmid
pcDNA3.1/Zeo(+)-PS1-WT using T7 or BGH primers (specific
to the plasmid DNA sequence) together with the corresponding
primers: L166P Rv: 59 CAG CAA CAA Taa gct tGA TAT AAT
AGG 39; L166P Fw: 59 CTT ATT ATA TCa agc ttA TTG TTG
CTG 39; P436Q Rv: 59 TCG AGT TTA Gaa gct tTC TTG AAA
ATG GCA AGG AG 39; P436Q Fw: 59 TCG AGT TTA Gaa gct
tTG CCA GCT CTT CAA ATC TCC 39. The sequences
corresponding to enzyme restriction sites are given in small letters.
The PCR fragments were next digested with BamHI/HindIII and
HindIII/XhoI respectively, and were subcloned into pcDNA3. PS1
D257A/D385A (DDAA) was obtained by subcloning the DraI/
XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1
D257A. The APP based substrate SPA4CT-Flag, corresponding
to the signal peptide of APP fused to the APP-C99-Flag with a
small linker region (DA) [36], was obtained by removing the
HindIII/EcoRI fragment of pcDNA3-APP695-Flag and inserting
the following annealed primers: 59 AGC TTA TGC TGC CCG
GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG
GCT CGG GCG GAT GCA GAT GCA G 39 and 59 AAT TCT
GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC
AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 39. All
constructs were next subcloned into the self-inactivated vector
pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain
Mind Institute, EPFL, Lausanne, Switzerland). Inserts for plasmids
pET21-C100-Flag, and pET21-C100-His were generated by PCR
as previously described [27]. Plasmids pMD2G and psPAX2 were
obtained from D. Trono (Global Health Institute, EPFL,
Lausanne, Switzerland).
Lentivector production
Replication-defective lentiviral particles were produced by a
three-plasmid transient transfection of cells from the human
embryonic kidney HEK 293T cell line [61]. Briefly, cells were
incubated in 10 cm dishes until they reached 70% confluence and
were transiently co-transfected by the calcium phosphate method,
with 5 mg of envelope plasmid (pMD2G), 15 mg of packaging
plasmid (psPAX2), and 20 mg of vector plasmids (pSIN-PGK-
WHV). Cells were incubated overnight with DNA-calcium
precipitates, washed twice with Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen) and incubated with 7 mL of
DMEM. After 24 h, the conditioned medium was harvested and
cells were incubated a second time with 7 mL of DMEM for 24 h.
Media were then pooled, passed through 0.45 mm filter, and
stored at 280uC as 2 mL aliquots until use. A p24 ELISA
(Zeptometrix corporation) was performed on each batch of media
in order to evaluate the number of viral particles generated.
Generation of stable cell lines through multiple gene
transductions
Mouse Embryonic Fibroblasts (MEFs, obtained from B. De
Strooper, Flanders University Institute of Biotechnology, Belgium)
defective in PSEN1 and PSEN2 [30,31] were cultivated in 10 cm
dishes in DMEM, supplemented with 10% foetal bovine serum
(FBS) and penicillin/streptomycin (P/S) (Invitrogen). A first set of
stable cell lines was generated by co-transducing NCT-V5,
APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV)
repeatedly for two weeks at each passage (1/20). Ten clones were
isolated by the limiting dilution method and were further screened
for NCT-V5, Flag-PEN2 and APH1aL-HA expression by
immunodetection. The clone that showed the highest expression
of the three proteins (designated c - PS1/2) was used as the
parental cell line to generate the stable cell lines expressing
different PS1 variants, by the same method and by using lentiviral
vectors carrying human PS1-WT, PS1-L166P, PS1-DE9, PS1-
P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA. For each PS1
variant, five clones were selected for a full characterization and
two of them were further used for c-secretase purification. For
SPA4CT overexpression experiments, 500,000 cells of each clone
were exposed to the same arbitrary dose of lentiviral vectors
carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S
and were plated in 6-wells plates for 72 h. The medium was next
replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell
culture medium was harvested, supplemented with protease
inhibitor cocktail (Roche), centrifuged for 3 min at 1,0006 rpm
and frozen at 280uC until further processing. Cells were washed
in PBS and submitted to protein extraction.
Protein extraction
Total protein extracts were prepared in 1% NP40 - HEPES
buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2,
5 mM CaCl2), supplemented with protease inhibitor cocktail
(Roche), and were clarified by centrifugation for 1 h at 16,0006g,
4uC. Cell membranes were obtained as described below and
solubilised in 1% CHAPSO - HEPES buffer and centrifuged at
16,0006 g for 1 h. Supernatants corresponding to the microsomal
protein extracts were harvested and stored at 280uC. Protein
content of the extracts was estimated by the BCA protein assay
reagent kit (Pierce).
Multi-step purification of human c-secretase complexes
with FAD-linked PS1 variants
1) Cell membrane preparation. MEF PS1/PS2 DKO cells (1.06109
cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different
forms of PS1: wild type (WT), or with FAD-linked variants or
lacking the critical aspartate residues, were collected from 15 cm
dishes and fully resuspended in 40 mL of MES buffer (50 mM
MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2),
supplemented with protease inhibitor cocktail (Roche). Next, cells
were passed four times through a high-pressure homogenizer
(Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater
than 1,000 psi. Nuclei and unbroken cells were removed by
centrifugation at 3,0006 g for 20 min at 4uC in a Beckman
Coulter Allegra X-15R centrifuge. The supernatant was collected
and centrifuged at 100,0006 g for 1 h at 4uC in a SW32Ti rotor
using a Beckman Coulter Optima L-80 ultracentrifuge to recover
the membrane preparation in the pellet. 2) Bicarbonate wash. The
membrane pellet was fully resuspended in 1.6 mL of ice cold
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sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by
pipetting up and down at least 30 times, and incubated at 4uC
for 20 min. The washed membranes were then centrifuged at
100,0006 g for 1 h at 4uC and stored at 280uC until use. 3)
Solubilisation of c-secretase complexes. The bicarbonate-washed mem-
branes were fully resuspended in 1.7 mL of 1% CHAPSO -
HEPES buffer by pipetting up and down at least 30 times. The
membranes were then incubated at 4uC for 1 h. To pellet the
insoluble material, the solution was centrifuged at 16,0006 g at
4uC for 1 h, the pellet was discarded, and the supernatant saved.
This lysate is defined as ‘‘solubilised c-secretase preparation’’.
Next, these freshly prepared solubilised preparations were used for
affinity purification of c-secretase complexes as described below. 4)
Anti-Flag M2 affinity purification. The solubilised c-secretase
preparations were first diluted 1:2 with HEPES buffer, and
further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl) (final detergent concentration:
0.08% CHAPSO, 0.08% digitonin) and incubated overnight at
4uC with agitation after adding 200 mL of anti-Flag M2 affinity
resin beads (Sigma-Aldrich) that had been pre-equilibrated in
0.1% Digitonin - TBS buffer. The beads were washed 3 times in
the same buffer, and the bound proteins were eluted over 4 h at
4uC with 0.4 mL of this buffer containing 200 mg/mL of Flag
peptides (Sigma-Aldrich). This elution step was repeated once for
1 h at 4uC and the eluted fractions were pooled and designated
‘‘M2 pooled 800 mL fractions’’. 5) Anti-V5 affinity purification. The
M2 pooled fractions (volume made up to 1 mL with 0.1%
Digitonin - TBS buffer) were next incubated overnight at 4uC
under agitation with 200 mL of anti-V5 affinity resin beads (Sigma-
Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer. The
beads were washed 3 times in the same buffer, and the bound
proteins were eluted for 1 h at 4uC with 0.4 mL of this buffer
containing 500 mg/mL of V5 peptides (Sigma-Aldrich). This
elution step was repeated 4 times, and the eluted fractions were
pooled and designated ‘‘V5 pooled 1.6 mL fractions’’. 6) Anti-HA
affinity purification. As a final purification step, the V5 pooled
fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS
buffer) were next incubated overnight at 4uC under agitation with
200 mL of anti-HA affinity resin beads (Sigma-Aldrich), pre-
equilibrated in 0.1% digitonin - TBS buffer. The beads were
washed 3 times in the same buffer, and the bound proteins were
eluted overnight at 4uC with 0.2 mL of this buffer containing
200 mg/mL of HA peptides (Sigma-Aldrich). This elution step was
repeated once, for 1 h at 4uC, and the two eluted fractions were
kept separately, designated ‘‘HA fraction E1’’ and ‘‘HA fraction
E2’’.
Co-immunoprecipitation
Co-IPs were performed on microsomal protein extracts. Briefly,
100 mg of proteins were diluted in a final volume of 1 mL of 1%
CHAPSO - HEPES extraction buffer containing protease
inhibitors (Roche), and 50 mL of pre-equilibrated anti-Flag or
anti-HA affinity beads (Sigma-Aldrich) were added. Samples were
next incubated overnight at 4uC on a rotator wheel and were
washed three times in 0.2% CHAPSO - HEPES buffer. Finally,
beads were resuspended in 50 mL of 0.2% CHAPSO - HEPES
buffer and were used for in vitro c-secretase assays.
In vitro c-secretase activity assays
In vitro c-secretase activity assays were performed as previously
described [27]. c-Secretase APP-based substrates were expressed
in E. coli transfected with plasmids pET21-C100-Flag or pET21-
C100-His as a fusion protein consisting of a Met for translation
initiation, and either the Flag tag sequence (C100-Flag) or the His
tag sequence (C100-His), and were affinity purified using an anti-
Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin
(Invitrogen), respectively. In vitro assays were performed at 37uC
for 4 h, with 1 mM of recombinant substrate, 0.025% phospha-
tidylethanolamine (PE) and 0.1% phosphatidylcholine (PC). c-
Secretase activity was quantified by measuring the amount of
AICD and Ab generated during the reaction, by immunoblot or
sandwich ELISA respectively, as described below.
SDS-PAGE, Native PAGE, Western blotting and antibodies
Total or microsomal protein extracts were resolved by
electrophoresis on NuPAGEH NovexH 4–12% Bis-Tris Gels
(Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris
Glycine gels for SDS-PAGE analysis. Purified c-secretase was
resolved by electrophoresis on NativePAGETM NovexH Bis-Tris
4–16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen).
Silver staining was performed directly on gel according to
manufacturer instructions (Biorad). For immunoblot analysis, gels
were transferred to nitrocellulose or PVDF membranes (What-
man), and probed with the following antibodies: anti-Nicastrin
NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance),
MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF,
MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA
(Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-
Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for b-
actin (Sigma-Aldrich). Anti-mouse/rabbit/rat IgG conjugated to
Alexa 680 were purchased from Invitrogen. The Odyssey infrared
imaging system (LICOR) was used to detect the fluorescent signal.
Quantification of Ab peptides
Ab peptides from the c-secretase assays described above were
quantified by sandwich ELISA according to the protocol provided
by the manufacturer. Three kits were used to detect human Ab1–
40 (Invitrogen KHB3481) and Ab1–42 (Invitrogen KHB3544 and
Wako 269-64401).
Supporting Information
Figure S1 Characterization of stable cell lines overex-
pressing human FAD-linked PS1 variants in MEF PS1/
22/2. Presenilin double-knockout mouse embryonic fibroblasts
were stably transduced with lentiviral vectors carrying genes
encoding hPS1 variants harbouring FAD-linked mutations or
mutations in the catalytic aspartate residue(s), or PS1-WT, and
cloned. Two clones per PS1 variant were selected for character-
ization. (A) Whole cell protein extracts of the different cell lines
were prepared in 1% NP40-HEPES buffer, separated by SDS-
PAGE on 12% Tris-Glycine gels and analysed by immunostaining
with various antibodies to detect the endogenous c-secretase core
components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2
(UD1), and with an antibody for APP (A8717). b-Actin was used as
a loading control. Each lane represents one selected clone. (B) c-
Secretase activity assays were performed with microsomal extracts
prepared in 1% CHAPSO-HEPES buffer. Equal protein levels
from the different extracts were diluted to 0.25% CHAPSO-
HEPES buffer and incubated for 4 h at 37uC with lipids and 1 mM
of recombinant human APP-based substrate (C100-Flag). Samples
were analyzed by SDS-PAGE and immunostained with anti-Flag
(M2) or anti-PS1 (MAB1563). PS1 immunostaining was used to
assess the amount of input material. * Indicates a non-specific
band, which was not detected in microsomal protein extracts of
the same cell lines using the same antibody (MAB1563) (B). CTF:
C-terminal fragment, FL: full-length, im.: immature NCT; m.:
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mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O:
O-glycosylated.
(TIF)
Figure S2 APP-CTF profiles in WT MEF, MEF PS1/22/2
and c - PS1/2 transduced with the SPA4CT construct.
WT MEF, MEF PS1/22/2 and c - PS1/2 were transduced with
an APP-based substrate corresponding to the 99 C-terminal
residues of human APP fused to the APP signal peptide in N-
terminus (SPA4CT [36]). Cell proteins were extracted in 1%
NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-
Glycine gels and analysed by immunostaining with an antibody
targeting the C-terminal part of APP (A8717).
(TIF)
Figure S3 APH1 isoforms expressed in MEF PS1/22/2.
Total RNAs were extracted from presenilin double-knockout
MEFs, using standard procedures (Qiagen RNAeasy kit) and were
quantified by spectrophotometry. One microgram of total RNAs
was reverse transcribed for 1 h at 42uC by using the ImProm-II
reverse transcription system (Promega) and oligo-dT primer in a
final volume of 20 mL. PCR was next performed for each APH1
isoform on 1 mL of RT reaction by using the Roche PCR kit under
standard conditions and the primers described in Table S1. The
following cycling conditions were applied for all reactions: 94uC,
3 min; 30 cycles of [94uC, 30 s; 58uC, 30 s; 70uC, 40 s]; 70uC,
10 min. PCR products were separated on a 2% agarose gel and
visualized using Alpha Innotech UV imager.
(TIF)
Table S1 Primers used to detect APH1 isoforms in MEF
PS1/22/2. F: Forward, R: Reverse.
(DOC)
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